Provided by Tiger Fintech (Singapore) Pte. Ltd.

Omeros

6.97
-0.1800-2.52%
Pre-market: 6.70-0.2697-3.87%08:57 EDT
Volume:697.13K
Turnover:5.04M
Market Cap:404.71M
PE:-2.59
High:7.67
Open:7.49
Low:6.94
Close:7.15
Loading ...

Press Release: Omeros Corporation to Announce Fourth Quarter and Year-end Financial Results on March 31, 2025

Dow Jones
·
26 Mar

Omeros Is Maintained at Buy by D. Boral Capital

Dow Jones
·
22 Mar

Omeros Says Trial Site Activation Underway for Phase 3 Study of Zaltenibart

MT Newswires Live
·
22 Mar

Omeros Corp - Phase 3 Data Needed for Bla Submission Expected in Q4 2026

THOMSON REUTERS
·
21 Mar

Omeros Corp - No Safety Signal of Concern Has Been Observed With Zaltenibart

THOMSON REUTERS
·
21 Mar

Omeros Corporation Provides Update of Ongoing Zaltenibart Phase 3 Pnh Clinical Trial Program

THOMSON REUTERS
·
21 Mar

Omeros Corporation Provides Update of Ongoing Zaltenibart Phase 3 PNH Clinical Trial Program

Business Wire
·
21 Mar

BRIEF-Omeros Corporation Receives Commitment Of Over $4 Million From Nida For Further Development Of The Company’S Oms527 Program To Treat Cocaine Use Disorder

Reuters
·
13 Mar

Omeros Corporation Receives Commitment of Over $4 Million From Nida for Further Development of the Company’s Oms527 Program to Treat Cocaine Use Disorder

THOMSON REUTERS
·
13 Mar

Top Premarket Decliners

MT Newswires Live
·
07 Mar

Investors Look for Signs of Tariff Easing as US Futures Rise Modestly Pre-Bell

MT Newswires Live
·
05 Mar

Omeros announces results for narsoplimab expanded access program

TipRanks
·
21 Feb

Omeros Corporation Announces Availability on its Website of Materials Accompanying Narsoplimab Presentations at the 2025 Tandem Meetings

Business Wire
·
14 Feb

OMER S.p.a. Receives ‘Buy’ Rating Following Strategic Luxury Train Project and Anticipated Revenue Growth

TIPRANKS
·
13 Feb

BRIEF-Omeros Corporation Announces Upcoming Presentations Detailing Outcomes Of Narsoplimab Treatment For Ta-Tma

Reuters
·
10 Feb

Omeros Corporation Announces Upcoming Presentations Detailing Outcomes of Narsoplimab Treatment for Ta-Tma Under an Expanded Access Program

THOMSON REUTERS
·
10 Feb

Omeros Corporation Announces Upcoming Presentations Detailing Outcomes of Narsoplimab Treatment for TA-TMA Under an Expanded Access Program

Business Wire
·
10 Feb

Institutions own 43% of Omeros Corporation (NASDAQ:OMER) shares but retail investors control 53% of the company

Simply Wall St.
·
10 Feb

OMER S.p.A. Receives Buy Rating: Strategic Expansion and Market Potential Highlighted

TIPRANKS
·
28 Jan

Needham Remains a Hold on Omeros (OMER)

TIPRANKS
·
17 Jan